Week Ending November 8, 2021

Meet the Visionary Defender of Early Detection and Prompt Treatment
“Dr. Rami Arfoosh, a pulmonologist, has been defending people with abnormal lung cancer screening exams for more than four years in northeast Georgia. With high rates of incidence and mortality, lung cancer is a dangerous and often silent killer for the residents of northeast Georgia. For Dr. Arfoosh, lung cancer screening, quick referrals and prompt treatment for people with newly diagnosed lung cancer are at the forefront of his daily work.”

Patient with Stage 4 ALK-Positive Lung Cancer Hasn’t Skipped a Beat, Thanks to Targeted Therapy
“Before Jeff Clark received an unexpected lung cancer diagnosis at age 42, he and his wife Kathy weren’t familiar with the disease.”

Unmet physical and psychological needs impact lung cancer patients’ quality of life
“Research published in the European Journal of Cancer Care suggests that unmet physical and psychological needs of patients with lung cancer have a significant impact on patients’ quality of life and affect their ability to continue with everyday activities.”

Screenings encouraged to detect, combat lung cancer in older adults
“DELMARVA – “Lung cancer was not on my radar. I had developed a case of bronchitis. My primary care doctor ordered a chest x-ray just to make sure I didn’t have pneumonia and they saw something on my lungs,” Lung Cancer Survivor & Advocate Deena Cook said.”

Lung Cancer Caught Early: Marylou’s Story
“Marylou Capes-Platt knew she was at an especially high risk for lung cancer. She had been a heavy smoker for 45 years, starting in her teens and continuing through a decades-long career in the music industry and as a writer and editor. She finally quit in 2007.”

More Lung Cancer Patients Are Surviving, Thriving
“Diagnosed with stage 4 lung cancer back in 2016, the 56-year-old South Carolina resident says there are a lot of reasons to be optimistic as the “narrative of lung cancer changes from being a horrific, terminal disease to a chronic disease and, ultimately, to a cure.”

Takeda launches value-based pricing program for lung cancer med Alunbrig, promises more deals to come
“As the targeted treatment space for ALK-positive non-small cell lung cancer becomes more crowded, Takeda is trying to get ahead of the competition with a drug pricing tool that’s rarely used among U.S. oncology players.”

Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck
“Bristol Myers Squibb and Merck are locked in a heated race to bring their blockbuster PD-(L)1 drugs into early cancer patients as part of potentially curative combinations. The approvals have been coming fast and heavy, and Bristol Myers keeps adding to its case for a big-time FDA nod in lung cancer.”

DEEP BENCH: Understanding Small Cell Lung Cancer
“WAUSAU, Wis. (WSAW) – November is Lung Cancer Awareness Month.”

Genetic testing saves advanced lung cancer patients
“ORLANDO, Fla. (Ivanhoe Newswire)— Lung cancer is the leading cause of cancer deaths for both men and women. The five-year survival rate for advanced non-small cell lung cancer, that has spread to distant areas of the body, is seven percent. However, doctors believe the key to increasing survival rates for advanced lung cancer patients is in the genes.”